drugset / Trial / NCT00163514

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

NCT00163514

Phase 3 Completed 636 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

Timeline

Start
2004-05
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciclesonide Other / unclassified 25 ug Intranasal
Subject Ciclesonide Other / unclassified 100 ug Intranasal
Subject Ciclesonide Other / unclassified 200 ug Intranasal